Skip to main content
Premium Trial:

Request an Annual Quote

Callida Genomics, Michele Delsanter


Callida Genomics, the microarray subsidiary of Hyseq Pharmaceuticals, has non-exclusively licensed its portfolio of microarray patents to Agilent Technologies for commercial use. Under the agreement, Callida will pay Agilent both up-front fees and any potential royalties.

“This agreement secures access to an important set of patents derived from Radoje Drmanac, currently CSO at Callida, who conducted pioneering work in the early development of microarrays,” Barney Saunders, vice president and general manager of Agilent’s Bioresearch Solutions, said in a statement.

Drmanac has been listed as the inventor on 16 US patents since 1991, the majority of which cover Callida’s Sequencing by Hybridization microarray technology.

“This agreement fits nicely with our licensing strategy for non-universal probes, further validating the strength of our patent portfolio and providing us with future royalty revenue opportunities,” stated George Rathmann, interim president, chairman, and CEO of Callida Genomics.

Michele Delsanter, DE Unterschleissheim, and Michael Galuszka of N rnberg, Germany, have been awarded German patent number DE0010048375A1, “Multifunctional and multiparametric biochip arrangement.” The patent provides a biochip with a sensor unit for measuring the components of body fluids or cell cultures, especially for measuring the components of capillary, venous, or arterial blood. The biochip has a micropump, a controller chip, and a transmitting and receiving unit, and the sensor unit consists of at least one sensor element as well as a reference system for continuous matching with the sensor element. Furthermore, a modular arrangement for measuring the components of body fluids or cell cultures as well as for regulating an organism is provided. This consists of a number of single elements put together according to requirements. The modular arrangement carries a biochip, at least one controlling system for electronic control, rechargeable batteries, a transmitter and receiver device, at least one unit consisting of a storage container, and a micropump for releasing substances.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.